Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence.
Fasching PA, Kreipe H, Del Mastro L, Ciruelos E, Freyer G, Korfel A, Chouaki N, Stoffregen C, Sapunar F, Cameron D. Fasching PA, et al. Among authors: sapunar f. Geburtshilfe Frauenheilkd. 2024 Feb 8;84(2):164-184. doi: 10.1055/a-2238-3199. eCollection 2024 Feb. Geburtshilfe Frauenheilkd. 2024. PMID: 38344042 Free PMC article.
Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2- Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice.
Ring A, Karuturi M, Smyth EN, Lokhandwala T, Sheffield KM, Willey J, Lunacsek O, Sapunar F, Cui ZL, Coutinho AD, Rybowski S. Ring A, et al. Among authors: sapunar f. Drugs Real World Outcomes. 2023 Dec;10(4):589-603. doi: 10.1007/s40801-023-00391-1. Epub 2023 Sep 29. Drugs Real World Outcomes. 2023. PMID: 37775689 Free PMC article.
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study.
Kuter I, Gee JM, Hegg R, Singer CF, Badwe RA, Lowe ES, Emeribe UA, Anderson E, Sapunar F, Finlay P, Nicholson RI, Bines J, Harbeck N. Kuter I, et al. Among authors: sapunar f. Breast Cancer Res Treat. 2012 May;133(1):237-46. doi: 10.1007/s10549-011-1947-7. Breast Cancer Res Treat. 2012. PMID: 22286314 Clinical Trial.
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M. Di Leo A, et al. Among authors: sapunar f. J Clin Oncol. 2010 Oct 20;28(30):4594-600. doi: 10.1200/JCO.2010.28.8415. Epub 2010 Sep 20. J Clin Oncol. 2010. PMID: 20855825 Clinical Trial.
23 results